Growing resistance tolast-line antibioticsCarbapenems are a major last-line class of antibiotics to treat bacterial infections.The spread of carbapenem-resistant infections is a threat to healthcare and patient safety in Europe as it seriously curtails the ability to cure infections.

5%of all countries have

guidance on infection control measures

on CRAb

25/38 countries reported a

certain stage

13/38 countries reported an

uncertain stage

15%of these countries have guidance on infection

control measureson CPE

76%of these countries have guidance on infection

control measureson CPE

Everyone is responsible.

2/38

2/1319/25

perform active

surveillanceand isolate

patients

hygi

ene

prec

autio

ns

cohort nursing by separate, dedicated team and equipment

prudent

antibiotic

use

Infection control measures

Use antibiotics prudently!

7/30

1/30

5/30

4/307/30

3/303/30

11/30

5/30

4/30

3/30 3/30

2/302/30

20132013

2010

No case Sporadic occurrenceSingle hospital outbreakSporadic hospital outbreaksRegional spreadInter-regional spreadEndemic situation

Nr. of countries / Countries surveyed

Carb

apne

m-re

sist

ant E

nter

obac

teriaceae (CPE) - Epidemiological stages

Carb

apne

m-re

sist

ant E

nter

obac

teriaceae (CPE) - Epidemiological stages

Carbapenemase-producing Acinetobacter baumannii (CRAb) - Epidemiological stages

Aminopenicillin

Aminoglycosides

Third-generation cephalosporins

Carbapenems

49.3%

39.3%

44.6%Aminoglycosides

Carbapenems

Fluoroquinolones

Acinetobacter spp.EU-mean resistance

6.2%

Carbapenems

Klebsiella pneumoniae

EU-mean resistance

Each year, 30 EU/EEA countries report data on antimicrobial resistance to the European Antimicrobial Resistance Surveillance Network (EARS-Net) and on antimicrobial consumption to the European Surveillance of Antimicrobial Consumption network (ESAC-Net). Both networks are hosted at ECDC. For the first time, 18 countries reported data on Acinetobacter spp. to EARS-Net. In addition, experts in 38 European countries participated in the European Survey on Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) done for ECDC by the University Medical Centre Groningen, The Netherlands.

The emergence and spread of antibiotic resistance, in other words the ability of bacteria to resist the action of an antibiotic, has become a recognised global problem. Antibiotic resistance severely limits the number of antibiotics available for the treatment of diseases.

Each year, 30 EU/EEA countries report data on antimicrobial resistance to the European Antimicrobial Resistance Surveillance Network (EARS-Net) and on antimicrobial consumption to the European Surveillance of Antimicrobial Consumption network (ESAC-Net). Both networks are hosted at ECDC.

25.3%Fluoroquinolones

22.2%

25.7%Third-generation cephalosporins

Aminoglycosides

Carbapenemconsumption in

hospitals

countries reported a significant

decrease

80 Carbapenem

s

countries reported a significantincrease

Carbapenems are one of doctors’ last possible choice of antibiotics to treat infections due to bacteria resistant to multiple antibiotics.

Many EU countries lack guidance on prevention and control of carbapenem-resistant infections.

Still low but increasing.

Limited options left for treatment.